The use of absorption enhancers to enhance the despersibility of spray-dried powders for pulmonary gene therapy

Journal of Gene Medicine

Volumn 7, Issue 8, 2005, Pages 1035-1043

  Li, H Y ^a   Seville, P C ^b   Williamson, I J ^c   Birchall, J C ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b ASTON UNIVERSITY   (United Kingdom)

^c ANEURIN BEVAN UNIVERSITY HEALTH BOARD   (United Kingdom)

Author keywords

Absorption enhancer; Deposition; Gene delivery; Lung; Non viral; Spray drying

Indexed keywords

BETA CYCLODEXTRIN DERIVATIVE; LIPID; PENETRATION ENHANCING AGENT; PLASMID DNA; POLYCATION; TREHALOSE;

ABSORPTION; ARTICLE; CONTROLLED STUDY; DRY POWDER; GEL ELECTROPHORESIS; GENE VECTOR; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LASER DIFFRACTION; LUNG; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PARTICLE SIZE; POWDER INHALER; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SPRAY DRYING;

ABSORPTION; CELL LINE, TUMOR; DNA; FLOW CYTOMETRY; GENE THERAPY; HUMANS; LUNG DISEASES; MODELS, BIOLOGICAL; PARTICLE SIZE; POWDERS; TRANSFECTION;

EID: 23944455043     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.749     Document Type: Article

References (41)

1. Rave K, Nosek L, Heinemann L, et al. Inhaled micronized crystalline human insulin using a dry powder inhaler: dose-response and time-action profiles. Diabet Med 2004; 21: 763-768.
2. Irngartinger M, Camuglia V, Damm M, Goede J, Frijlink HW. Pulmonary delivery of therapeutic peptides via dry powder inhalation: effects of micronisation and manufacturing. Eur J Pharm Biopharm 2004; 58: 7-14.
3. Tobyn M, Staniforth JN, Morton D, Harmer Q, Newton ME. Active and intelligent inhaler device development. Int J Pharm 2004; 277: 31-37.
4. Nakate T, Yoshida H, Ohike A, Tokunaga Y, Ibuki R, Kawashima Y. Formulation development of inhalation powders for FK888 with carrier lactose using Spinhaler and its absorption in healthy volunteers. J Control Release 2004; 97: 19-29.
5. Fiegel J, Fu J, Hanes J. Poly(ether-anhydride) dry powder aerosols for sustained drug delivery in the lungs. J Control Release 2004; 96: 411-423.
6. Bronsky EA, Grossman J, Henis MJ, et al. Inspiratory flow rates and volumes with the Aerolizer dry powder inhaler in asthmatic children and adults. Curr Med Res Opin 2004; 20: 131-137.
7. Asada M, Takahashi H, Okamoto H, Tanino H, Danjo K. Theophylline particle design using chitosan by the spray drying. Int J Pharm 2004; 270: 167-174.
8. Chan HK, Clark AR, Feeley JC, et al. Physical stability of salmon calcitonin spray-dried powders for inhalation. J Pharm Sci 2004; 93: 792-804.
9. Codrons V, Vanderbist F, Verbeeck RK, et al. Systemic delivery of parathyroid hormone (1-34) using inhalation dry powders in rats. J Pharm Sci 2003; 92: 938-950.
10. Todo H, Iida K, Okamoto H, Danjo K. Improvement of insulin absorption from intratracheally administrated dry powder prepared by supercritical carbon dioxide process. J Pharm Sci 2003; 92: 2475-2486.
11. Todo H, Okamoto H, Iida K, Danjo K. Improvement of stability and absorbability of dry insulin powder for inhalation by powder-combination technique. Int J Pharm 2004; 271: 41-52.
12. Lucas P, Anderson K, Potter UJ, Staniforth JN. Enhancement of small particle size dry powder aerosol formulations using an ultra low density additive. Pharm Res 1999; 16: 1643-1647.
13. Kawashima Y, Serigano T, Hino T, Yamamoto H, Takeuchi H. A new powder design method to improve inhalation efficiency of pranlukast hydrate dry powder aerosols by surface modification with hydroxypropylmethylcellulose phthalate nanospheres. Pharm Res 1998; 15: 1748-1752.
14. Zeng XM, Martin AP, Marriott C, Pritchard J. The influence of carrier morphology on drug delivery by dry powder inhalers. Int J Pharm 2000; 200: 93-106.
15. Zeng XM, Martin GP, Marriott C, Pritchard J. Lactose as a carrier in dry powder formulations: the influence of surface characteristics on drug delivery. J Pharm Sci 2001; 90: 1424-1434.
16. Li HY, Neill H, Innocent R, Seville P, Williamson I, Birchall JC. Enhanced dispersibility and deposition of spray-dried powders for pulmonary gene therapy. J Drug Target 2003; 11: 425-432.
17. Li HY, Seville PC, Williamson IJ, Birchall JC. The use of amino acids to enhance the aerosolisation of spray-dried powders for pulmonary gene therapy. J Gene Med 2005; 7: in press; DOI: 10.1002/jgm.654.
18. Gao X, Huang L. Potentiation of cationic liposome-mediated gene delivery by polycations. Biochemistry 1996; 35: 1027-1036.
19. Li S, Huang L. In vivo gene transfer via intravenous administration of cationic lipid-protamine-DNA (LPD) complexes. Gene Ther 1997; 4: 891-900.
20. Li S, Rizzo MA, Bhattacharya S, Huang L. Characterization of cationic lipid-protamine-DNA (LPD) complexes for intravenous gene delivery. Gene Ther 1998; 5: 930-937.
21. Sorgi FL, Bhattacharya S, Huang L. Protamine sulfate enhances lipid-mediated gene transfer. Gene Ther 1997; 4: 961-968.
22. Lee VH, Yamamoto A, Kompella UB. Mucosal penetration enhancers for facilitation of peptide and protein drug absorption. Crit Rev Ther Drug Carrier Syst 1991; 8: 91-192.
23. Muranishi S. Absorption enhancers. Crit Rev Ther Drug Carrier Syst 1990; 7: 1-33.
24. el-Hariri LM, Marriott C, Martin GP. The mitigating effects of phosphatidylcholines on bile salt- and lysophosphatidylcholine-induced membrane damage. J Pharm Pharmacol 1992; 44: 651-654.
25. Hussain A, Arnold JJ, Khan MA, Ahsan F. Absorption enhancers in pulmonary protein delivery. J Control Release 2004; 94: 15-24.
26. Hussain A, Yang TZ, Zaghloul AA, Ahsan F. Pulmonary absorption of insulin mediated by tetradecyl-β-maltoside and dimethyl-β-cyclodextrin. Pharm Res 2003; 20: 1551-1557.
27. Li Y, Mitra AK. Effects of phospholipid chain length, concentration, charge, and vesicle size on pulmonary insulin absorption. Pharm Res 1996; 13: 76-79.
28. Johansson F, Hjertberg E, Eirefelt S, Tronde A, Hultkvist Bengtsson U. Mechanisms for absorption enhancement of inhaled insulin by sodium taurocholate. Eur J Pharm Sci 2002; 17: 63-71.
29. Kagatani S, Shinoda T, Fukui M, Ohmura T, Hasumi S, Sonobe T. Enhancement of nasal salmon calcitonin absorption by lauroylcarnitine chloride in rats. Pharm Res 1996; 13: 739-743.
30. Kagatani S, Inaba N, Fukui M, Sonobe T. Nasal absorption kinetic behavior of azetirelin and its enhancement by acylcarnitines in rats. Pharm Res 1998; 15: 77-81.
31. Shimazaki T, Tomita M, Sadahiro S, Hayashi M, Awazu S. Absorption-enhancing effects of sodium caprate and palmitoyl carnitine in rat and human colons. Dig Dis Sci 1998; 43: 641-645.
32. Kobayashi S, Kondo S, Juni K. Pulmonary delivery of salmon calcitonin dry powders containing absorption enhancers in rats. Pharm Res 1996; 13: 80-83.
33. Srichana T, Suedee R, Reanmongkol W. Cyclodextrin as a potential drug carrier in salbutamol dry powder aerosols: the in-vitro deposition and toxicity studies of the complexes. Respir Med 2001; 95: 513-519.
34. Kinnarinen T, Jarho P, Jarvinen K, Jarvinen T. Pulmonary deposition of a budesonide/gamma-cyclodextrin complex in vitro. J Control Release 2003; 90: 197-205.
35. Birchall JC, Kellaway IW, Gumbleton M. Physical stability and in vitro gene expression efficiency of nebulised lipid-peptide-DNA complexes. Int J Pharm 2000; 197: 221-231.
36. Larhrib H, Martin GP, Marriott C, Prime D. The influence of carrier and drug morphology on drug delivery from dry powder formulations. Int J Pharm 2003; 257: 283-296.
37. Ahsan F, Arnold JJ, Yang T, Meezan E, Schwiebert EM, Pillion DJ. Effects of the permeability enhancers, tetradecylmaltoside and dimethyl-beta-cyclodextrin, on insulin movement across human bronchial epithelial cells (16HBE14o-). Eur J Pharm Sci 2003; 20: 27-34.
38. Mahesh Kumar T, Misra A. Pulmonary absorption enhancement of salmon calcitonin. J Drug Target 2004; 12: 135-144.
39. Snell NJ, Ganderton D. Assessing lung deposition of inhaled medications. Consensus statement from a workshop of the British Association for Lung Research, held at the Institute of Biology, London, UK, on 17 April 1998. Respir Med 1999; 93: 123-133.
40. Yang T, Hussain A, Paulson J, Abbruscato TJ, Ahsan F. Cyclodextrins in nasal delivery of low-molecular-weight heparins: in vivo and in vitro studies. Pharm Res 2004; 21: 1127-1136.
41. Chavan V, Dalby R. Novel system to investigate the effects of inhaled volume and rates of rise in simulated inspiratory air flow on fine particle output from a dry powder inhaler. AAPS PharmSci 2002; 4: E6.